<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994266</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-0912-CU</org_study_id>
    <nct_id>NCT00994266</nct_id>
  </id_info>
  <brief_title>Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy</brief_title>
  <official_title>Efficacy of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Diamel (dietary supplement)
      administration in the treatment of patients with type 2 diabetes receiving insulin therapy.
      The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks.
      The estimated number of patients to be recruited and randomized for the study is 116. Daily
      insulin requirements, blood glucose (fasting and post-prandial) concentrations, glycosylated
      hemoglobin (HbA1c), triglycerides and cholesterol will be assessed at the beginning and after
      24 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of insulin daily doses at week 24 and at the beginning of the study</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of glucose concentrations (fasting and post-prandial) at week 24 and at the beginning of the study considering the adjusted insulin doses during treatment</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hypoglycemic episodes during treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of HbA1c concentrations at week 24 and at the beginning of the study</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of triglycerides and cholesterol concentrations at week 24 and at the beginning of the study</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diamel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diamel</intervention_name>
    <description>Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with insulin therapy regimen of two daily doses.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Type 1 diabetes.

          -  Type 2 diabetes with glibenclamide treatment.

          -  Nephropathy or liver condition diagnosed by clinical and/or biochemical examination.

          -  Sepsis.

          -  Pregnancy.

          -  HbA1c values greater than 10%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Elena de la Uz Herrera, MSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Abel Santamaría Cuadrado&quot; General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arturo Hernández Yero, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Care Center. &quot;Abel Santamaría Cuadrado&quot; General Hospital</name>
      <address>
        <city>Pinar del Río</city>
        <zip>20200</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Maria Elena de la Uz Herrera</name_title>
    <organization>&quot;Abel Santamaría Cuadrado&quot;General Hospital</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Diamel</keyword>
  <keyword>Dietary supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

